Year 2021 (55)

Edition nr. 12


Reduction of cardiovascular risk with fish oil (Vazkepa)

In 2021, EMA published a favourable advisory report on the benefit-risk balance of the drug icosapent ethyl (EPA), branded as Vazkepa®, after which it was authorised for use in Europe. A large randomised placebo-controlled registration study foun ...

In short Read article


New oral contraceptive containing estetrol

Summary Drovelis®, a contraceptive pill containing the new oestrogen estetrol, was recently authorised for the European market by EMA. The reliability of this pill, which combines estetrol with drospirenone has not been assessed in controlled st ...

In short Read article